CClinicalTrials.gg
CompletedNCT04824274Updated Feb 24, 2022

TAP Block With Intrathecal Fentanyl vs. Intrathecal Morphine in Cesarean Delivery

An interventional study of fentanyl and morphine in Cesarean Section, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-02-24.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Study summary

This noninferiority study aims to determine whether transversus abdominis plane (TAP) block with intrathecal fentanyl could provide a noninferior analgesia compared with intrathecal morphine after cesarean delivery under spinal anesthesia.

Read the detailed description

Healthy mothers scheduled to undergo elective cesarean delivery under spinal anesthesia will be randomly allocated to receive either TAP block plus intrathecal fentanyl (Group TF) or intrathecal morphine (Group M).

Primary outcome is pain score with movement at postoperative 24 hours.

02

Conditions studied

  • Cesarean Section

Keywords

  • transversus abdominis plane block
  • morphine
  • fentanyl
  • spinal anesthesia
  • cesarean section
  • postoperative analgesia
03

In context

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Adult full-term parturients scheduled to undergo elective cesarean delivery under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Contraindication to spinal anesthesia
  • Any chronic pain unrelated pregnancy
  • current opioid medication use
  • BMI more than 40 kg m-2
  • History of drug allergy or hypersensitivity to fentanyl, morphine, ropivacaine, acetaminophen, NSAIDs, bupivacaine, ramosetron, ondansetron, nalbuphine, Naloxone, metoclopramide
  • infection of abdominal wall
  • Pregnancy-induced hypertension
  • known cardiovascular disease
  • Known fetal anomaly
  • Any sign of onset of labor
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Transversus abdominis plane block and intrathecal fentanyl

    Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + fentanyl 10 mcg. Following the completion of surgery, ultrasound-guided bilateral transversus abdominis plane block will be done with 0.375% ropivacaine 15 ml per each side.

    Drug: fentanyl · Procedure: Transversus abdominis plane block

  • Active comparator
    Intrathecal morphine

    Patients will receive spinal anesthesia with 0.5% bupivacaine 9 mg + morphine 75 mcg. Following the completion of surgery, sham block will be done using normal saline.

    Drug: morphine · Procedure: Sham block

Interventions

  • Drugfentanyl

    Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.

  • Drugmorphine

    Morphine 75 mcg will be injected intrathecally during spinal anesthesia.

    Also known as: Morphine sulfate

  • ProcedureTransversus abdominis plane block

    Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.

  • ProcedureSham block

    Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.

06

What researchers measure

Primary outcomes

  1. Pain score with movement at 24 hours after delivery

    Pain score with movement at 24hr after delivery, using 11-point Numeric rating scale (0, no pain; 10, the worst pain imaginable)

    Time frame: at 24 hours after delivery

Secondary outcomes

  1. Intravenous fentanyl consumption

    cumulative fentanyl consumption via intravenous patient-controlled analgesia

    Time frame: at 6, 12, 18, 24, 48 hours after delivery

  2. Pain score at rest

    Pain score at rest using 11-point Numeric rating scale (0, no pain; 10, the worst pain imaginable)

    Time frame: at 6, 12, 18, 24, 48 hours after delivery

  3. Pain score with movement

    Pain score with movement using 11-point Numeric rating scale (0, no pain; 10, the worst pain imaginable)

    Time frame: at 6, 12, 18, 48 hours after delivery

  4. time to first opioid request

    time to first intravenous fentanyl administration from delivery

    Time frame: during hospital stay, an average of 3 days

  5. number of patients requiring rescue analgesics

    number of patients requiring rescue analgesics

    Time frame: During the first 48 hour-period after delivery

  6. Incidence of nausea

    Proportion of patients who experienced nausea

    Time frame: During the first 48 hour-period after delivery

  7. Incidence of vomiting

    Proportion of patients who experienced vomiting

    Time frame: During the first 48 hour-period after delivery

  8. Incidence of pruritus

    Proportion of patients who experienced pruritus

    Time frame: During the first 48 hour-period after delivery

  9. Incidence of sedation

    Proportion of patients who experienced sedation

    Time frame: During the first 48 hour-period after delivery

  10. Incidence of respiratory depression

    Proportion of patients who experienced respiratory depression

    Time frame: During the first 48 hour-period after delivery

  11. Nausea severity

    Nausea severity using 4-point scale with 0=none, 1=mild, 2=moderate, or 3=severe

    Time frame: During the first 48 hour-period after delivery

  12. Pruritus severity

    Pruritus severity using 4-point scale with 0=none, 1=mild, 2=moderate, or 3=severe

    Time frame: During the first 48 hour-period after delivery

  13. Patient satisfaction for overall postoperative managements using 11-point scale (0=totally unsatisfied; 10=totally satisfied)

    Patient satisfaction score for overall postoperative pain managements using 11-point scale (0=totally unsatisfied; 10=totally satisfied)

    Time frame: During the first 48 hour-period after delivery

  14. Hospital length of stay

    Hospital length of stay (day)

    Time frame: From admission to hospital discharge, an average of 3 days

  15. Apgar Score

    Apgar Score of fetus

    Time frame: at 1 minute, at 5 minutes

  16. Umbilical arterial pH

    Umbilical arterial pH

    Time frame: immediately after delivery

  17. Umbilical arterial PO2

    Umbilical arterial PO2

    Time frame: immediately after delivery

  18. Umbilical arterial PCO2

    Umbilical arterial PCO2

    Time frame: immediately after delivery

07

Study locations

1 site
  • Jin-Tae Kim
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Cole J, Hughey S, Longwell J. Transversus abdominis plane block and intrathecal morphine use in cesarean section: a retrospective review. Reg Anesth Pain Med. 2019 Sep 13:rapm-2019-100483. doi: 10.1136/rapm-2019-100483. Online ahead of print. PubMed 31519816 ↗
  • Patel SD, Sharawi N, Sultan P. Local anaesthetic techniques for post-caesarean delivery analgesia. Int J Obstet Anesth. 2019 Nov;40:62-77. doi: 10.1016/j.ijoa.2019.06.002. Epub 2019 Jun 8. PubMed 31262444 ↗
  • Kwikiriza A, Kiwanuka JK, Firth PG, Hoeft MA, Modest VE, Ttendo SS. The analgesic effects of intrathecal morphine in comparison with ultrasound-guided transversus abdominis plane block after caesarean section: a randomised controlled trial at a Ugandan regional referral hospital. Anaesthesia. 2019 Feb;74(2):167-173. doi: 10.1111/anae.14467. Epub 2018 Nov 1. PubMed 30383289 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04824274
Lead sponsor
Seoul National University Hospital
Responsible party
Jin-Tae Kim (Professor, Seoul National University Hospital) — Principal investigator
First posted
Apr 1, 2021
Start date
Apr 12, 2021
Primary completion
Feb 18, 2022
Completion
Feb 20, 2022
Last update
Feb 24, 2022

Study contacts

Jin-Tae Kim, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion